Softgel encapsulation of high-purity omega-3-acid ethyl esters is governed by thermoxidative stability constraints rather than compressibility or dissolution performance. A prescription-grade oral softgel fill matrix is formulated with 900 mg to 1,000 mg omega-3-acid ethyl esters per capsule; alpha-tocopherol is included at 0.2% to 0.4% w/w of the oil phase to limit free-radical propagation, and the fill is blanketed with nitrogen during storage and transfer. Ph. Eur. monograph 2063 for omega-3-acid ethyl esters 90 defines the sum of eicosapentaenoic acid ethyl ester and docosahexaenoic acid ethyl ester at 80.0% to 88.0% and total omega-3-acid ethyl esters at ≥90.0%. Oxidation limits are anchored to Ph. Eur. 2.5.7 for peroxide value at ≤5.0 meq O₂/kg and Ph. Eur. 2.5.36 for anisidine value at ≤20.0, aligning with the GOED Voluntary Monograph. Residual solvent compliance is assessed under ICH Q3C(R8); dissolution of the finished softgel is evaluated with USP 711 using surfactant-containing media because the API is practically insoluble in water. Rotary die softgel encapsulation is performed on production-scale machines with gel ribbon thickness 0.7 mm to 1.0 mm, fill temperature maintained at 25°C to 35°C, and die roll cooling to prevent shell leakage caused by low-viscosity oil penetration. Tunnel drying at 20°C to 25°C and 20% to 40% relative humidity reduces shell moisture to 6% to 8%; fill weight drift on multi-head rotary fill pumps is kept within ±3% of target to meet content uniformity expectations. The finished dosage form is a 1 g prescription omega-3-acid ethyl ester softgel for oral administration, used as an adjunct to diet in adults with severe hypertriglyceridemia. Published data for exact headspace oxygen thresholds in continuous rotary die runs remain limited; the operational boundary is therefore controlled by peroxide value and fill viscosity trending rather than a single validated oxygen setpoint.

Why Does Roller Compaction Precede Direct Compression for Omega-3 Loaded Granules?

Solid-dose conversion of omega-3 pharma-grade API into tablets or two-piece hard capsules requires microencapsulation of the oil phase onto a carrier matrix because the liquid ethyl ester or triglyceride substrate cannot be directly compressed. Spray-dried encapsulated omega-3 powders are manufactured from oil-in-water emulsions containing modified starch, gum arabic or maltodextrin; the resulting powders carry oil loads of 40% to 70% w/w and surface free oil ≤0.5% w/w. For a tablet label claim of 300 mg EPA+DHA per tablet, a 50% oil-load powder requires 600 mg powder, which occupies 37.5% of a 1,600 mg tablet core. Direct compression at this inclusion level is limited by Hausner ratios above 1.4 and potency segregation exceeding 5% relative standard deviation in unmodified powder blends; roller compaction is therefore inserted before tablet compression. Roller compaction is run with roll gap 1.5 mm to 2.5 mm, granulator screen 0.8 mm to 1.2 mm, and subsequent lubrication with magnesium stearate at 0.5% to 1.0% w/w. Tablet compression hardness is set to 80 N to 150 N to achieve disintegration times ≤30 min by USP 701 and acceptable dissolution by USP 711. Compliance testing includes USP 61 for total aerobic microbial count, USP 62 for specified pathogens, USP 616 for powder flow, USP 922 for water activity ≤0.4, and ICH Q3C(R8) for residual solvents from the encapsulation process. At ambient relative humidity above 60%, the encapsulated powder must be pre-dried in a fluid-bed dryer at 35°C to 40°C for 20 min to 30 min before blending. The finished product is a film-coated tablet or two-piece pharmaceutical-grade hard capsule for oral administration. A comparative powder characterization matrix is provided below.

Sachet Granule Uniformity and Oxidation Control in Pediatric Oral Powders

Fluid-bed granulation of omega-3 APIs for stick-pack and sachet formats prioritizes dose uniformity and oxidative stability in low-water-activity environments. A granule formulation for a single-dose sachet contains 20% to 35% w/w encapsulated omega-3 powder, 50% to 65% w/w isomalt or mannitol, 5% to 10% w/w hydroxypropyl methylcellulose binder, and 0.5% to 1.0% w/w citric acid as a pH modifier and metal-chelating antioxidant synergist. Granulation is performed in top-spray fluid-bed units with inlet air temperature 50°C to 65°C, product temperature 30°C to 38°C, and spray rate 20 g/min/kg to 40 g/min/kg bed load. Dried granules are passed through a 1.0 mm sieve and must show loss on drying ≤2.0% w/w by USP 731 before filling into aluminum triplex laminate stick packs. Content uniformity is tested by USP 905 with acceptance value ≤15.0, and aerobic microbial limits follow USP 61 and USP 62. Stability protocols follow ICH Q1A(R2) zones I and II with peroxide value retest at 0, 3, 6, 12, and 24 months. The oxidative stability of the granule matrix is controlled by limiting iron and copper residues to ≤0.1 ppm each because trace transition metals accelerate Fenton-type hydroperoxide decomposition; this is an absolute incompatibility boundary for long-duration ambient storage. Finished sachet products deliver 250 mg to 500 mg EPA+DHA per unit and are used as oral dispersible granules for pediatric, geriatric and dysphagia populations where softgel swallowing is not feasible. The terminal product type is a single-dose oral granule sachet or multidose powder bottle, not a tablet or softgel. Published data for specific pediatric age-group formulation optimization is limited, so dose adjustment is typically based on body weight and clinical assessment rather than fixed monograph dissolution profiles.

When injectable omega-3 triglycerides are prepared as part of a parenteral lipid emulsion, the API must be refined fish oil triglycerides rather than omega-3-acid ethyl ester concentrate because the ethyl ester form is not suitable for intravenous administration. In a 20% total lipid injectable emulsion, the fish oil phase typically constitutes 10% to 15% of the total oil phase, corresponding to 2 g to 3 g fish oil per 100 mL; the other oil components are soybean oil, medium-chain triglycerides and olive oil. The aqueous phase contains glycerol 2.25% to 2.5% w/v, egg lecithin 1.2% w/v, and water for injection, adjusted to pH 6.0 to 9.0 before terminal sterilization. Residual solvents are controlled by ICH Q3C(R8). High-pressure homogenization is run at 400 bar to 600 bar for 5 to 8 passes, with recirculation through a plate heat exchanger to keep product temperature below 60°C. Globule size is controlled to mean diameter ≤500 nm and large-diameter tail PFAT5 ≤0.05% by USP 729; sub-visible particulate contamination is monitored by Ph. Eur. 2.9.20. Terminal sterilization is carried out by rotating autoclave at 121°C for 15 min. Oxygen exposure is limited by nitrogen overlay in the oil storage and homogenization feed vessels, and the finished emulsion is filled into multilayered non-PVC bags with oxygen barrier properties. The finished product type is a sterile injectable lipid emulsion for parenteral nutrition, delivered as a single-chamber or multi-chamber bag with fish oil as part of the lipid phase. Incompatibility with cationic electrolyte concentrates and high calcium chloride additions must be considered; emulsion destabilization occurs when calcium concentrations exceed the emulsion-specific critical aggregation threshold. Published data for this specific emulsion configuration is limited, but the acceptance limits of USP 729 are the standard control point in manufacturing and release.

Enteral Formula Oil-in-Water Emulsions Do Not Tolerate Softgel-Shell Moisture Profiles

In enteral clinical nutrition, hospital and long-term care formulas incorporate omega-3 pharma-grade oil as a minor lipid phase in sterilizable oil-in-water emulsions designed for sip feeding or tube administration. Fish oil addition is typically 0.2% to 1.5% w/w of the liquid formula, supplying 0.5 g to 1.0 g EPA+DHA per 1,000 kcal in immune-modulating and critical care products. The oil phase is combined with caseinate or whey protein concentrate, maltodextrin and emulsifiers under high-shear mixing, followed by two-stage homogenization at 150 bar to 250 bar and UHT sterilization at 137°C to 142°C for 3 s to 8 s. Formula osmolality is adjusted to 300 mOsm/kg to 500 mOsm/kg for tube feeding tolerance. Compliance for products intended for disease-related malnutrition is governed by EU Regulation (EU) No 609/2013 on foods for special medical purposes; where a conventional food claim is made in the United States, 21 CFR 101.83 applies to combined EPA and DHA intake declarations. The finished product is a ready-to-hang enteral nutrition bottle, 200 mL sip feed, or 1,000 mL tube-feeding bag. This product format is not interchangeable with injectable lipid emulsions; the microbial and particulate control pathway is designed for enteral administration only. The operational boundary for UHT processing is the delta between spoilage safety and omega-3 oxidation: higher time-temperature treatments reduce microbial load but increase anisidine-reactive oxidation products; therefore, aseptic filling and deaeration are more critical than extending heat exposure.